ACCESS Newswire

The newsfeed available here is provided by our content partner ACCESS Newswire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public.

The NewsWire Hub ("X-Billboard") currently comprises five of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and form a complementary information offering that covers more than three quarters of the official news sources on which editorial offices worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 21
5.224,53 S&P · 27,25 Vola-Index · 87.066,89 BTC · 1,15414 EURUSD
System-State: Number of processed items 10.104 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              

ACCESS Newswire is an important news source for private investors, investors and traders that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market players in one central location. If you want to get a quick overview, you can easily scroll through the headlines. Those who want to take a closer look at the news can use the detailed views of the info cards to directly access the respective news item and other analysis tools.

NEWS
EXPLORER
NL0015436031
State: 21.04.2025 | 3PM
Do you already know our new terminal view? Click here.
FIGI: BBG00W9LXXJ4
CVAC
CureVac N.V.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
NAME
CureVac N.V.
ISIN
NL0015436031
TICKER
CVAC
MIC
XNAS
REUTERS
CVAC.OQ
BLOOMBERG
CVAC US
Thu, 10.04.2025       CureVac
NL0015436031

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate TransformationCompleted enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout anticipated in H2 2025Filed IND and CTA submissions for Phase 1 study with proprietary off-the-shelf ...
Read More
CureVac
Technical Analysis Termsheet Terminal
Permalink
Tue, 08.04.2025       CureVac
NL0015436031

TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2024 on Thursday,...
Read More
CureVac
Technical Analysis Termsheet Terminal
Permalink
Mon, 07.04.2025       CureVac
NL0015436031

Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancerProprietary Epitopes: CVHNLC encodes novel tumor epitopes identified through proprietary whole genome-based discovery platformEnhanced Combination Therapy: CVHNLC to be tested in combination w...
Read More
CureVac
Technical Analysis Termsheet Terminal
Permalink
Thu, 27.03.2025       CureVac
NL0015436031

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended formA hearing on infringement of EP 3 708 668 B1 is scheduled for July 1, 2025, before the Regional Court DüsseldorfConfirming validity of patent in its amended form marks major mile...
Read More
CureVac
Technical Analysis Termsheet Terminal
Permalink
Tue, 18.02.2025       CureVac
NL0015436031

CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolioThe company holds one of the broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / February 18, 2025 / CureVac N...
Read More
CureVac
Technical Analysis Termsheet Terminal
Permalink
Tue, 12.11.2024       CureVac
NL0015436031

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific...
Read More
CureVac
Technical Analysis Termsheet Terminal
Permalink
Thu, 07.11.2024       CureVac
NL0015436031

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and ...
Read More
CureVac
Technical Analysis Termsheet Terminal
Permalink
Mon, 04.11.2024       CureVac
NL0015436031

Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (&...
Read More
CureVac
Technical Analysis Termsheet Terminal
Permalink
Mon, 04.11.2024       CureVac
NL0015436031

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that new and updated data will be shared in two oral presentations and...
Read More
CureVac
Technical Analysis Termsheet Terminal
Permalink
Mon, 28.10.2024       CureVac
NL0015436031

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced poster presentations at the Society for Immunotherapy of Cancer (SITC)...
Read More
CureVac
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the international investor community, we would like to thank AccessWire for providing the news and data feeds